Is the natural product screening activity declining?
Abstracts of Asian Mycological Congress 2000, Hong Kong SAR, China. 9-13 July 2000. 32p.
The expectation toward fungal metabolites was tremendous since blockbuster drugs such as mevalotina and cyclosporine were launched more than a decade ago. During these years, meanwhile, technologies for drug discovery process have been highly advanced and diversified. Pharmaceutical industries are keeping up with heavy competition with high-throughput screening (HTS), combinatorial chemistry and genomics. The better-faster-cheaper strategy tends to dive out the natural products screening (NPS) programs, which take time and cost much. Recently, we took a survey of the NPS activities by sending questionnaires to various organizations mainly in Japan. 73% of them are conducting NPS. However, they are facing difficulties including pure technological problems to cope with HTS and more political issues such as Conventions on Biological Diversity. I will discuss trends and future in the NPS programs form a viewpoint of mycology. I will also touch on discussions on collaboration between Asian countries and Japan’s biological resource center.論文リストに戻る
Reprint request to Toru Okuda
Last update on
Copyright © TorulopsisOktavianus